Revolution Medicines, Inc.
RVMDNASDAQHealthcare● Active
$149.23
$-6.46(-4.15%)
Market Cap$31.7B
P/E Ratio—
52W High$166.5
52W Low$34
Revolution Medicines, Inc. (RVMD) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RVMD · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.01B | $0.04B | $0.03B |
| Cost of Revenue | $0.02B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.02B) | $0.00B | $0.01B | $0.04B | $0.03B |
| Gross Margin %(computed) | — | — | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.98B | $0.59B | $0.42B | $0.25B | $0.19B |
| G&A Expenses | $0.19B | $0.10B | $0.08B | $0.04B | $0.03B |
| Total Operating Expenses | $1.17B | $0.69B | $0.50B | $0.29B | $0.22B |
| Operating Income | ($1.18B) | ($0.69B) | ($0.49B) | ($0.26B) | ($0.19B) |
| Operating Margin %(computed) | — | — | — | -730.01% | -639.70% |
| Interest Income | $0.09B | $0.09B | $0.05B | $0.01B | $0.00B |
| Interest Expense | $0.02B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($1.13B) | ($0.60B) | ($0.44B) | ($0.25B) | ($0.19B) |
| Income Tax Expense | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B |
| Net Income | ($1.13B) | ($0.60B) | ($0.44B) | ($0.25B) | ($0.19B) |
| Net Margin %(computed) | — | — | — | -702.95% | -636.58% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.47 |
| Wtd Avg Shares | 0.19B | 0.17B | 0.11B | 0.08B | 0.07B |
| EBITDA | ($1.09B) | ($0.68B) | ($0.48B) | ($0.25B) | ($0.18B) |
| EBITDA Margin %(computed) | — | — | — | -702.72% | -611.59% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Revolution Medicines, Inc. data
About Revolution Medicines, Inc. (RVMD) Income Statement
Revolution Medicines, Inc. (RVMD) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RVMD reported revenue of $0.00B, gross profit of ($0.02B) (gross margin —), and net income of ($1.13B) — a net profit margin of —.
Frequently asked questions
RVMD · 4 questionsRevolution Medicines, Inc. (RVMD) reported revenue of $0.00B for 2025, down —% year-over-year.
RVMD revenueRVMD salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08